Check for updates

OPEN ACCESS

EDITED BY Xiangyu Fan, University of Jinan, China

REVIEWED BY Agnieszka Kwiatek, University of Warsaw, Poland Yuhang Wang, The University of Iowa, United States

*CORRESPONDENCE Tonglei Wu ⊠ 532966952@163.com

RECEIVED 20 December 2024 ACCEPTED 27 January 2025 PUBLISHED 10 February 2025

CITATION

Zhang L, Chen L, Zhang X, Li Y, Zheng Q, Li Y, Li N, Shi Q, Zhang Y and Wu T (2025) The *mcpC* mutant of *Salmonella enteritidis* exhibits attenuation and confers both immunogenicity and protective efficacy in mice. *Front. Microbiol.* 16:1548920.

doi: 10.3389/fmicb.2025.1548920

COPYRIGHT

© 2025 Zhang, Chen, Zhang, Li, Zheng, Li, Li, Shi, Zhang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The *mcpC* mutant of *Salmonella enteritidis* exhibits attenuation and confers both immunogenicity and protective efficacy in mice

Lu Zhang¹, Li Chen¹, Xuqiang Zhang¹, Yang Li¹, Qingfeng Zheng², Yun Li³, Ning Li⁴, Qiumei Shi¹, Yanying Zhang¹ and Tonglei Wu¹*

¹Hebei Key Laboratory of Preventive Veterinary Medicine, College of Animal Science and Technology, Hebei Normal University of Science and Technology, Qinghuangdao, China, ²Qinhuangdao Animal Husbandry Station, Qinghuangdao, China, ³Shijiazhuang Animal Products and Veterinary Drug Feed Quality Testing Center, Shijiazhuang, China, ⁴Tangshan Academy of Agricultural Sciences, Tangshan, China

Background: Salmonella enteritidis (SE) is a Gram-negative, facultative anaerobic intracellular pathogen that not only causes disease and mortality in livestock and poultry but also contaminates animal-derived products, leading to foodborne illnesses in humans. This presents a significant threat to public health. To eliminate this pathogen, the development of novel vaccines targeting *SE* is imperative. Attenuated live vaccines are capable of eliciting robust immune protection against *SE*.

Methods: In this study, an *mcpC* gene deletion strain ($\Delta mcpC$) was constructed by the wild strain C50336, to evaluate its potential as a genetically engineered attenuated live vaccine. The virulence of $\Delta mcpC$ was assessed by examining its resistance to environmental stresses, biofilm formation capacity, motility, adhesion, invasion ability, intracellular survival, LD₅₀, expression levels of virulence genes, and *in vivo* colonization ability. Furthermore, the immunogenicity of $\Delta mcpC$ was analyzed in mice by measuring specific IgG and SIgA antibody levels, lymphocyte proliferation, cytokine expression, and the protective efficacy of $\Delta mcpC$ vaccination.

Results: Compared to the wild-type strain, $\Delta mcpC$ exhibited no significant changes in biofilm formation or adhesion to Caco-2 cells. However, $\Delta mcpC$ showed significantly reduced survival under acidic, alkaline, thermal, and oxidative stress conditions; markedly diminished motility; weakened invasion of Caco-2 cells; and reduced intracellular survival in RAW264.7 macrophages. The LD₅₀ of $\Delta mcpC$ increased by 30-fold, and the expression levels of certain virulence genes were significantly downregulated. Additionally, $\Delta mcpC$ demonstrated significantly decreased colonization in the liver, spleen, and cecum of mice, indicating attenuated virulence. Immunization with $\Delta mcpC$ induced the production of specific IgG and SIgA antibodies, enhanced lymphocyte proliferation, upregulated cytokine expression, and achieved a 100% survival rate in immunized mice. These findings indicate that $\Delta mcpC$ provides effective immune protection in mice.

Conclusion: This study demonstrates that deletion of the mcpC gene attenuates the virulence of SE. The $\Delta mcpC$ offers strong immune protection in mice, providing a solid foundation for the development of genetically engineered attenuated live vaccines against SE.

KEYWORDS

Salmonella enteritidis, mcpC, gene deletion, virulence, vaccine

Background

Salmonella enteritidis (SE) is a significant zoonotic pathogen that not only inflicts substantial economic losses on the livestock industry but has also emerged as one of the predominant serotypes causing salmonellosis in humans in recent years (Zhou et al., 2023; Chousalkar et al., 2018). While strict biosecurity measures can create Salmonellafree poultry farming environments, such measures are often economically unfeasible in many countries. Moreover, the widespread emergence of multidrug-resistant strains has raised concerns about the use of antibiotics. Vaccination remains a primary strategy for controlling Salmonella infections. Currently, inactivated vaccines, subunit vaccines, and live attenuated vaccines represent the major categories of Salmonella vaccines under development (Huberman et al., 2019).

Studies indicate that inactivated vaccines primarily induce humoral immunity and fail to elicit robust cell-mediated immune responses. As a result, booster immunizations are often required to achieve long-term protection (Deguchi et al., 2009). Subunit vaccines, while safe, typically require multiple doses to extend the duration of immunity and necessitate suitable adjuvants to trigger effective cellular immune responses. In contrast, live attenuated vaccines, when administered orally, adhere to the intestinal mucosa and mimic natural infection, thereby eliciting strong humoral and cell-mediated immune responses (Van Immerseel et al., 2005). The identification of virulence genes is crucial for developing gene-deletion-based live vaccines. This approach has been successfully employed in the development of various vaccines, including those for Brucella spp., Salmonella Typhimurium, Yersinia pestis, Vibrio anguillarum, and Edwardsiella tarda (Yang et al., 2015; Liu et al., 2018; Park et al., 2020; Cote et al., 2021; Zabalza-Baranguá et al., 2023).

SE must overcome multiple defense mechanisms inside and outside the gastrointestinal tract to establish infection in the host. Upon entering the digestive system, the first challenge it encounters is the bactericidal effect of gastric acid. Gastric acid, being a strongly acidic environment, inhibits or kills most microorganisms that reach the stomach. To survive, SE expresses high levels of acid shock proteins, such as ATPase, which help maintain intracellular pH balance and enhance its resistance to gastric acid. In the intestine, SE defends itself against bile and digestive enzymes by regulating its lipopolysaccharide (LPS) structure and producing anti-bile proteins, such as TolC. In the small intestine, it utilizes a type III secretion system (T3SS) to secrete effector molecules, including SipA, SipB, and SipC, which facilitate its invasion of intestinal epithelial cells. Within host cells, Salmonella forms a specialized membrane-bound compartment called the Salmonella-containing vacuole (SCV), which protects it from lysosomal degradation. After being phagocytosed by macrophages, SE injects T3SS effectors like SifA and SipC to inhibit the fusion of SCVs with lysosomes. Additionally, Salmonella can evade autophagy-mediated clearance by secreting effectors such as SseJ, allowing it to persist and proliferate within the SCV. In summary, the infection process of SE involves adapting to gastric acid, resisting bile, invading intestinal epithelium, evading the immune system, surviving intracellularly, and inducing inflammation. Each step relies on specific virulence factors and adaptive mechanisms, enabling *Salmonella* to establish infection in the gastrointestinal tract and beyond, leading to host disease. The loss of these virulence factors significantly attenuates the pathogen's virulence. Consequently, researchers have utilized these virulence factors to develop various gene-deletion vaccines, achieving promising immune protection results.

Methyl-accepting chemotaxis protein C (McpC) is a methylation-based chemotaxis protein involved in bacterial chemotaxis, enabling directional movement in response to chemical gradients. By sensing and transmitting environmental chemical signals, McpC helps bacteria regulate their motility. This chemotactic ability is crucial for pathogenic bacteria to colonize and spread within the host, thereby playing a significant role in virulence. Additionally, McpC is involved in regulating biofilm formation, flagellar biosynthesis, and toxin production (Hickman et al., 2005; Berleman and Bauer, 2005; Harkey et al., 1994). As such, modulating McpC expression or function in pathogens may impact their infection efficiency and pathogenicity, making McpC a key target for studying bacterial virulence and infection mechanisms. Previous studies have demonstrated the role of methyl-accepting chemotaxis proteins (MCPs) in the pathogenicity of various bacteria, including Pseudomonas aeruginosa, Campylobacter jejuni, and Vibrio cholerae (Li et al., 2014; Sampedro et al., 2014; Nishiyama et al., 2016). Based on these findings, it is hypothesized that McpC contributes to the virulence of SE, a hypothesis that requires further experimental validation. By precisely deleting the mcpC gene, the pathogen's virulence is significantly reduced while retaining its immunogenicity, thereby greatly enhancing safety and efficacy. Moreover, the vaccine strain produced by deleting the presumed virulence-associated gene mcpC can induce robust mucosal, cellular, and humoral immune responses, making it suitable for non-injection administration methods such as oral or spray vaccination, which facilitates largescale application.

In this study, we constructed an *mcpC* gene deletion strain ($\Delta mcpC$) using homologous recombination techniques and investigated its impact on *SE* virulence. The evaluation included analyses of stress resistance, biofilm formation, motility, adhesion, invasion, intracellular survival in macrophages, LD₅₀, expression levels of virulence genes, and bacterial load in host organs. Additionally, we assessed the ability of $\Delta mcpC$ to induce immune responses and its protective efficacy in mice using an infection model. The findings provide a foundational basis for the development of genetically engineered live-attenuated vaccines targeting *SE*.

Materials and methods

Bacterial strains, cells and plasmids

Bacterial strains and plasmids used in this study are listed in Table 1. *Salmonella enteritidis* strain C50336, a wild-type strain, was preserved in the Key Laboratory of Preventive Veterinary Medicine, Hebei Province, and used for constructing the $\Delta mcpC$ strain. The *mcpC* gene deletion strain in this study was constructed using the

TABLE 1 Bacterial strains and plasm	ids used in this study.
-------------------------------------	-------------------------

Strains	Relevant characteristics	Sources	
C50336	Salmonella enterica serovar Enteritidis, wild-type	This study	
$\Delta mcpC::cat$	A first recombination strain	This study	
$\Delta mcpC$	A second recombination strain	This study	
$\Delta mcpC + mcpC$	Δ <i>mcpC</i> -complemented strain	This study	
	1		
Plasmids	Characteristics	Sources	
	Template plasmid; FRT- <i>aphT</i> -FRT (containing chloramphenicol	Datsenko and	
pKD3	resistance gene)	Wanner (2000)	
pKD46		Wanner (2000) Datsenko and Wanner (2000)	

 λ -Red recombinase-mediated gene replacement method (Datsenko and Wanner, 2000). The bacteria were cultured in Luria-Bertani (LB) broth (Haibo Biotechnology Co., Ltd.) at 37°C unless otherwise specified. Human epithelial Caco-2 BBE cells and mouse macrophage RAW264.7 cells used in this study were provided by BeNa Culture Collection (Shanghai, China). Both cell types were cultured in DMEM (Thermo Fisher Scientific Co., Ltd.) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific Co., Ltd.). Antibiotics were added as necessary, such as 50 µg/mL streptomycin and 50 U/mL penicillin, or 50 µg/mL gentamicin, in an incubator with 5% CO₂.

Experimental animals and ethical statement

Kunming (KM) mice were obtained from Beijing Speifu Biotechnology Co., Ltd. All animal experiments were conducted in full compliance with international ethical standards and the Experimental Animal Regulation Ordinances (HPDST 2020-17) as stipulated by the Hebei Provincial Department of Science and Technology. The study protocol was reviewed and approved by the Animal Care and Use Committee of Hebei Normal University of Science and Technology.

Construction of the *mcpC* deletion strain and complemented strain

C50336 (pKD46) was cultured in Luria-Bertani agar (LBA) containing 225 mg/mL L-arabinose at 30°C until the optical density (OD) at 600 nm reached 0.6–0.8. The cells were then washed three times with pre-chilled autoclaved ultrapure water to prepare electrocompetent cells. Using DH5 α (pKD3) as a template, a homologous targeting fragment was amplified with specific primers P1 and P2 (Table 2). The purified fragment was electroporated into electrocompetent C50336 (pKD46) cells. Subsequently, 1 mL of LB broth was added, and the cells were

incubated at 30°C for 2 h. The culture was then plated onto LB agar containing 50 µg/mL chloramphenicol (Cm). Colonies were identified using primers P3 and P4 (Table 2). Positive strains were cured of the pKD46 plasmid by incubation at 42°C and were designated as $\Delta mcpC::cat$.

To remove the Cm cassette, the pCP20 plasmid was introduced into $\Delta mcpC::cat$ via electroporation. Mutants were identified using primers P3 and P4, and positive strains were cured of the pCP20 plasmid by incubation at 42°C, resulting in the final $\Delta mcpC$ strain.

For the construction of the complemented strain, the open reading frame of the *mcpC* gene was amplified using primers P5 and P6 (Table 2). The purified PCR product was cloned into the pMD-19 T vector [Takara Biomedical Technology (Beijing) Co., Ltd.], resulting in the recombinant plasmid pMD-19 T-*mcpC*. This plasmid was then introduced into $\Delta mcpC$ by electroporation, and transformants were confirmed using primers P5 and P6. The complemented strain was designated as $\Delta mcpC + mcpC$.

In vitro stress simulation experiments

Overnight cultures of C50336, $\Delta mcpC$ and $\Delta mcpC + \Delta mcpC$ were washed three times with physiological saline and enumerated using the traditional plate counting method to determine the initial bacterial count. The bacterial suspensions were then subjected to static incubation under various stress conditions: physiological saline at pH 3.5, physiological saline at pH 10, and at 42°C for 1 h. Additionally, the bacterial suspensions were exposed to physiological saline containing 10 mmol/L H₂O₂ for 10 min. After stress treatment, bacterial counts were determined, representing the post-stress bacterial count. The survival rate of each strain under different conditions was calculated as follows: survival rate = (post-stress bacterial count)/(initial bacterial count).

Biofilm formation assay

The crystal violet (CV) staining method was used to assess biofilm formation (Zhang et al., 2020). Bacterial suspensions of C50336, $\Delta mcpC$, and $\Delta mcpC + mcpC$ were inoculated at a 1:100 ratio into glass tubes containing 6 mL of LB broth and incubated statically at 28°C for 3 days. The tubes were washed 2–3 times with PBS, fixed with anhydrous methanol for 15 min, and stained with 2% CV for 15 min. The presence and thickness of stained bacterial rings on the tube walls were observed.

For quantitative analysis, a 96-well plate assay was performed. Each well was inoculated with 150 μ L of bacterial suspension and stained as described above. After staining, 200 μ L of anhydrous ethanol was added to each well to dissolve the CV. Absorbance at 570 nm was measured, and the experiment was repeated three times.

To detect two major components of the biofilm, curli fimbriae and cellulose, 5 μ L of bacterial suspension from C50336, $\Delta mcpC$, and $\Delta mcpC + mcpC$ was spotted onto salt-free LB agar containing 160 mg/L Congo red and 10 mg/L Coomassie brilliant blue (for curli detection) or onto agar containing 200 mg/L Calcofluor White Stain (CWS) for cellulose detection. Plates were incubated at 28°C for 2 days. Colony color, morphology, and fluorescence intensity under UV light (366 nm) were observed (Dong et al., 2011).

Primer	Sequence (5′−3′)
P1:	AGCAGCTCATGTTACTGGATGAAGAGGGGGCGCTGGAGCCAGAGTTCGCAGAAAGAGCTGTGTGTG
P2:	CGCACGCGCCGCTTCAACCGCCGCGTTCAGCGCCAGAATATTGGTCTGAAAGGCAATGGCATATGAATATCCTCCTTAG
Р3:	CGCTCTGTCTTTGTTTAGCCTTGA
P4:	ATCCCTTCCTGAGTCTGACTGGTT
P5:	GAAAATATGTTTTTGCATAACATTAAAA
Р6:	TTAAGCGGGCTGCGTGTCCTCTTCGCGGA

TABLE 2 Primers used for constructing the mutant and the complemented strain.

Motility assay

Bacterial motility was assessed using semi-solid agar plates (0.3% agar). Briefly, 5 μ L of overnight bacterial culture was carefully inoculated into the center of the semi-solid agar plate by gently stabbing it with a pipette tip to avoid agitation. Plates were incubated upright at 37°C for 5–6 h. Motility was determined by observing the migration of bacteria from the inoculation site toward the periphery of the plate. The experiment was repeated three times (Eakley et al., 2011).

Adhesion, invasion, and intracellular survival assays

Bacterial suspensions of C50336, $\Delta mcpC$, and $\Delta mcpC + mcpC$ were washed three times with PBS and enumerated using CFU calculations from serial dilutions on agar plates. Caco-2 BBE cells were seeded into 12-well plates at a density of 10⁵ CFU/well and cultured overnight in antibiotic-free DMEM supplemented with 10% FBS to achieve 80% confluence. The cells were washed three times with sterile PBS, and 1 mL of bacterial suspension was added to each well at a multiplicity of infection (MOI) of 100. Plates were centrifuged at 1,000 rpm for 5 min and incubated in a 37°C, 5% CO₂ incubator for 1 h (Xiong et al., 2023).

Adhesion assay

After a 1-h incubation, the cells were washed three times with PBS and lysed with 1% Triton X-100 for 8 min. The cell lysates were serially diluted and plated on SS agar for bacterial enumeration. Adhesion rate = (number of adhered bacteria/number of bacteria in the inoculum per well) \times 100%.

Invasion assay

After a 1-h incubation, the cells were washed three times with PBS and further incubated for 1 h in DMEM containing gentamicin (100 μ g/mL) to kill extracellular bacteria. The cells were then lysed with 1% Triton X-100 for 8 min, and the lysates were plated for bacterial enumeration. Invasion rate = (number of intracellular bacteria/number of bacteria in the inoculum per well) × 100%.

For the intracellular survival assay, RAW264.7 cells were seeded at a density of 10^5 cells per well into two 12-well plates. Cells were infected with bacteria at an MOI of 100 and incubated at 37° C with 5% CO₂ for 2 h. Non-adherent and non-invaded bacteria were removed by washing the cells twice with PBS. The cells were then incubated for 1 h in DMEM containing 100 µg/mL gentamicin to

eliminate remaining extracellular bacteria. The cells were lysed with 1% Triton X-100, and intracellular bacteria were enumerated, representing the bacterial count at 3 h post-infection. For the second plate, the cells were further incubated in DMEM containing 10 μ g/mL gentamicin for 20 h. Cells were then lysed with 1% Triton X-100, and intracellular bacteria were enumerated to represent the bacterial count at 23 h post-infection. Intracellular survival rate = (intracellular bacteria at 23 h/intracellular bacteria at 3 h) × 100%.

Determination of LD₅₀ in mice

Eighty KM mice aged 4 to 6 weeks were randomly divided into 16 groups (n = 5). The first five groups were intraperitoneally (i.p.) injected with C50336 at doses of 2×10^7 , 2×10^6 , 2×10^5 , 2×10^4 , and 2×10^3 CFU/mouse, respectively. The second five groups were i.p. injected with $\Delta mcpC$ at doses of 3.8×10^9 , 3.8×10^8 , 3.8×10^7 , 3.8×10^6 , and 3.8×10^5 CFU/mouse, respectively. The third five groups were i.p. injected with $\Delta mcpC + mcpC$ at doses of 2×10^7 , 2×10^6 , 2×10^5 , 2×10^4 , and 2×10^3 CFU/mouse, respectively. The third five groups were i.p. injected with $\Delta mcpC + mcpC$ at doses of 2×10^7 , 2×10^6 , 2×10^5 , 2×10^4 , and 2×10^3 CFU/mouse, respectively. The remaining group was i.p. injected with an equal volume of PBS. The mortality of the mice was observed and recorded over a 14-day period following the injection (Yin et al., 2019).

The LD₅₀ value was calculated using the formula of \log_{10} (50% endpoint) = A + (B × C), where A = \log_{10} (infectious dose showing a mortality next below 50%), B = difference of logarithms = [50% – (mortality at infectious dose next below 50%)]/ [(mortality next above 50%) – (mortality next below 50%)], and C = \log_{10} (difference between serial infectious doses used in challenge studies) (Park et al., 2022).

RNA extraction and quantitative real-time PCR

To further investigate the effect of the *mcpC* gene on the virulence of *SE*, quantitative real-time PCR (qPCR) was employed to analyze the expression levels of *SE* virulence-related genes after the deletion of the *mcpC* gene. The procedure was as follows: RNA was extracted using a bacterial RNA extraction kit (Beijing Aidlab Biotechnologies Co., Ltd.), and genomic DNA was removed via DNase I treatment. The RNA was then reverse-transcribed into cDNA using a reverse transcription kit (Bohang Biotechnology Co., Ltd.). This cDNA was used as the template for qPCR analysis with the SYBR Green dye method. The UltraSYBR Mixture used in this method is from Jiangsu Cowin Biotech Co, Ltd. Virulence factor-related genes and their primers were selected based on previously reported literature (Table 3), with the *16S rRNA* gene serving as the internal control (Frye et al., 2006; Upadhyaya et al., 2013). The qPCR thermal cycling

TABLE 3 Primers used for qPCR.

Gene	Sequence (5′–3′)
<i>fimD-</i> F	CGCGGCGAAAGTTATTTCAA
fimD-R	CCACGGACGCGGTATCC
<i>flgG</i> -F	GCGCCGGACGATTGC
<i>flgG-</i> R	CCGGGCTGGAAAGCATT
prot6E-F	GAACGTTTGGCTGCCTATGG
prot6E-R	CGCAGTGACTGGCATCAAGA
csgA-F	AATGCCACCATCGACCAGTG
csgA-R	CAAAACCAACCTGACGCACC
csgD-F	GCCTCATATTAACGGCGTG
csgD-R	AGCGGTAATTTCCTGAGTGC
bcsA-F	GCCCAGCTTCAGAATATCCA
bcsA-R	TGGAAGGGCAGAAAGTGAAT
ompR-F	TGTGCCGGATCTTCTTCCA
ompR-R	CTCCATCGACGTCCAGATCTC
hflK-F	AGCGCGGCGTTGTGA
hflK-R	TCAGACCTGGCTCTACCAGATG
tatA-F	AGTATTTGGCAGTTGTTGATTGTTG
tatA-R	ACCGATGGAACCGAGTTTTTT
<i>lrp</i> -F	TTAATGCCGCCGTGCAA
lrp-R	GCCGGAAACCAAATGACACT
sipA-F	CAGGGAACGGTGTGGAGGTA
<i>sipA</i> -R	AGACGTTTTTGGGTGTGATACGT
sipB-F	GCCACTGCTGAATCTGATCCA
sipB-R	CGAGGCGCTTGCTGATTT
<i>pipB</i> -F	GCTCCTGTTAATGATTTCGCTAAAG
<i>pipB</i> -R	GCTCAGACTTAACTGACACCAAACTAA
invH-F	CCCTTCCTCCGTGAGCAAA
invH-R	TGGCCAGTTGCTCTTTCTGA
mgtC-F	CGAACCTCGCTTTCATCTTCTT
mgtC-R	CCGCCGAGGGAGAAAAAC
sodC-F	CACATGGATCATGAGCGCTTT
sodC-R	CTGCGCCGCGTCTGA
<i>orf2</i> 45-F	CAGGGTAATATCGATGTGGACTACA
<i>orf245-</i> R	GCGGTATGTGGAAAACGAGTTT
<i>rfbH</i> -F	ACGGTCGGTATTTGTCAACTCA
<i>rfbH-</i> R	TCGCCAACCGTATTTTGCTAA
xthA-F	CGCCCGTCCCCATCA
xthA-R	CACATCGGGCTGGTGTTTT
mrr1-F	CCATCGCTTCCAGCAACTG
mrr1-R	TCTCTACCATGAACCCGTACAAATT
16S rRNA-F	CCAGGGCTACACACGTGCTA
16S rRNA-R	TCTCGCGAGGTCGCTTCT

conditions were as follows: initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.

Bacterial colonization and persistence in organs

Thirty-five 4–6-week-old KM mice were randomly divided into two groups: the C50336 infection group (Group A, n = 20) and the $\Delta mcpC$ infection group (Group B, n = 15). Mice in Group A were i.p. injected with the wild-type strain C50336, while mice in Group B were i.p. injected with the gene-deleted strain $\Delta mcpC$. The injection dose for both groups was 2×10^5 CFU/mouse. On days 3, 7, and 14 postinfection, five mice were randomly selected from each group and euthanized. Under sterile conditions, the liver, spleen, and cecum were collected, weighed, and homogenized in 1 mL of sterile PBS. Serial dilutions of the homogenate were plated on SS agar for bacterial enumeration. The bacterial load in each organ was calculated using the formula log₁₀ CFU/g (Negi et al., 2007; Milanez et al., 2018).

Immunization with $\Delta mcpC$ in mice

Twenty-four 6 to 8-week-old female KM mice were randomly divided into two groups: the immunized group (n = 12) and the control group (n = 12). The immunized group received an oral dose (p.o.) of 2×10^7 CFU/mouse of the $\Delta mcpC$ strain. The procedure was as follows: after fasting and water deprivation for 6 h, each mouse was orally administered 100 µL of 5% NaHCO₃ to neutralize gastric acid. Two hours later, oral inoculation was performed using a gavage needle. On day 14 post-immunization (dpi), a booster immunization with the same dose was administered. The control group received an equivalent volume of PBS via oral administration.

Detection of IgG and IgA

The indirect ELISA method was employed to detect SE-specific IgG and IgA in the serum and feces of immunized mice. The strain C50336 was cultured to the logarithmic growth phase, washed twice with PBS, and resuspended. The suspension was ultrasonically lysed for 30 min at 4°C, followed by centrifugation at 8,000 rpm for 10 min. The supernatant was collected and stored at -80° C for use as the coating antigen (Ji et al., 2022). At 14 dpi and 28 dpi, blood samples were randomly collected from three mice in the immunized group and three in the control group. The blood was centrifuged to separate the serum, which was stored at -80°C for IgG detection. Fecal samples were also collected from the same three mice. Five fecal pellets from each mouse were suspended in 0.5 mL of extraction buffer containing 0.1 mg/mL soybean trypsin inhibitor (Shanghai Yuanye Bio-Technology Co., Ltd.), 10 mg/mL bovine serum albumin (Biofroxx), and 30 mM EDTA disodium (pH 7.6). After homogenization and centrifugation, the supernatant was collected and stored at -80°C for IgA detection (Nandre et al., 2011; Pasquevich et al., 2011).

Using a checkerboard titration method, the optimal antigen coating concentration and sample dilution were determined. The coating antigen (500 ng/100 μ L) was added to a 96-well microtiter plate and incubated overnight at 4°C. Blocking was performed using

5% skim milk (prepared in PBS containing 0.05% Tween 20, PBST) at 37°C for 4 h (200 μ L/well). After removing the blocking solution, the plate was washed three times with PBST. Serum samples diluted 1:400 or undiluted fecal supernatant (100 μ L/well) were added and incubated at 37°C for 1 h. The plate was then washed three times with PBST. HRP-conjugated goat anti-mouse IgG (diluted 1:10,000, Beijing Solarbio Science & Technology Co., Ltd.) or HRP-conjugated goat anti-mouse IgA (diluted 1:10,000, Beijing Pulilai Gene Technology Co., Ltd.) was added at 100 μ L/well and incubated at 37°C for 1 h. Following another washing step, 100 μ L of TMB substrate solution (Beijing Solarbio Science & Technology Co., Ltd.) was added to each well and incubated at 37°C for 10 min. The reaction was terminated by adding 50 μ L of 2 M H₂SO₄ to each well, and the OD_{450nm} was measured (Park et al., 2022).

Lymphocyte proliferation assay

The C50336 bacterial antigen was prepared following the previously described method and used as a stimulant for the lymphocyte proliferation assay. At 14 dpi and 28 dpi, three mice from each group were euthanized. The spleens of the immunized mice were aseptically isolated, homogenized, and filtered through a 70 μ m cell strainer (Beijing Labgic Technology Co., Ltd.) to obtain spleen cells. Red blood cells were lysed using a red blood cell lysis buffer (Beijing Solarbio Science & Technology Co., Ltd.). The spleen lymphocytes were suspended in RPMI Medium 1,640 (Thermo Fisher Scientific Co., Ltd.) supplemented with 10% fetal bovine serum (FBS), 50 U/mL penicillin, and 50 μ g/mL streptomycin. Cell viability was assessed using the trypan blue exclusion test, and cells were counted using a hemocytometer.

In a 96-well tissue culture plate, 10^5 cells/100 µL of cell suspension were added to each well. For the stimulation group, bacterial antigen was added at a final concentration of 7.5 µg/mL (11 µL/well). For the non-stimulation group, 11 µL of RPMI Medium 1,640 containing 10% FBS, 50 U/mL penicillin, and 50 µg/mL streptomycin was added to each well. A medium-only control group was also included (111 µL/well). The 96-well tissue culture plates were incubated at 37°C in a humidified environment with 5% CO₂ for 72 h. Lymphocyte proliferation was measured using the MTT Cell Proliferation and Cytotoxicity Assay Kit (Shanghai Beyotime Biotechnology Co., Ltd.). Absorbance was measured at 450 nm, and the stimulation index (SI) was calculated as follows (Lin et al., 2017):

$$SI = \begin{pmatrix} Mean OD \text{ value of stimulation group} - \\ Mean OD \text{ value of medium} - \text{ only group} \end{pmatrix} / \\ \begin{pmatrix} Mean OD \text{ value of non} - \\ \text{stimulation group} - \\ Mean OD \text{ value of} \\ \text{medium} - \text{ only group} \end{pmatrix}$$

The expression of cytokines in the spleen

qPCR was used to evaluate the expression levels of cytokines *IL*-1β, *IL*-2, *IL*-4, *IL*-6, *IL*-10, *IFN*-γ, and *TNF*-α in the spleen of immunized

mice. At 14 dpi and 28 dpi, three mice from each group were randomly selected. Spleens were aseptically isolated, and total RNA was extracted using the TriQuick Total RNA Extraction Kit (Beijing Solarbio Science & Technology Co., Ltd.). DNA was removed by DNase I treatment, and RNA was reverse transcribed into cDNA using a reverse transcription kit (Bohang Biotechnology Co., Ltd.). Samples were stored at -80° C until use. RT-PCR for gene expression studies was performed using UltraSYBR Mixture (Jiangsu Cowin Biotech Co, Ltd., China).

The primers used for the qPCR are shown in Table 4. Cytokine expression levels were normalized to the internal control gene *gapdh* and β -actin and calculated using the $2^{-\Delta\Delta C_{T}}$ method. Thermal cycling conditions: initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min (Wang et al., 2021; Kang et al., 2022).

Immune protection assessment in mice

Forty 6 to 8-week-old KM female mice were randomly divided into four groups (n = 10): the immunization groups (Group A and Group B), the challenge group (Group C), and the control group (Group D). Mice in Group A were orally administered 2×10^7 CFU/mouse of $\Delta mcpC$, with a booster immunization at the same dose at 14 dpi. Mice in Group B were orally administered 2×10^6 CFU/mouse of $\Delta mcpC$, also with a booster immunization at the same dose at 14 dpi. Mice in Groups C and D were orally administered an equivalent volume of PBS. At 28 dpi, mice in the immunization groups (Groups A and B) and the challenge group (Group C) were i.p. injected with 2×10^7 CFU/ mouse of C50336, while mice in the control group (Group D) were i.p. injected with an equivalent volume of PBS. For 14 days post-challenge, mouse mortality was recorded daily, and the relative survival rate was calculated as follows:

TABLE 4 Primers used for the qPCR amplification of cytokines.

Primers	Sequence (5′–3′)
<i>IL-1β-</i> F	GACTGTTTCTAATGCCTTCCC
$IL-1\beta$ -R	ATGGTTTCTTGTGACCCTGA
<i>IL-2-</i> F	TGAGCAGGATGGAGAATTACAGG
IL-2-R	GTCCAAGTTCATCTTCTAGGCAC
<i>IL-4-</i> F	GGTCTCAACCCCCAGCTAGT
IL-4-R	GCCGATGATCTCTCTCAAGTGAT
<i>IL-6-</i> F	TAGTCCTTCCTACCCCAATTTCC
<i>IL-6-</i> R	TTGGTCCTTAGCCACTCCTTC
<i>IL-10-</i> F	CTTACTGACTGGCATGAGGATCA
<i>IL-10-</i> R	GCAGCTCTAGGAGCATGTGG
<i>IFN-γ-</i> F	ATGAACGCTACACACTGCATC
<i>IFN-γ-</i> R	CCATCCTTTTGCCAGTTCCTC
<i>TNF-α</i> -F	CCCTCACACTCAGATCATCTTCT
<i>TNF-α</i> -R	GCTACGACGTGGGCTACAG
GAPDH-F	AGGTCGGTGTGAACGGATTTG
GAPDH-R	TGTAGACCATGTAGTTGAGGTCA
β -Actin-F	TTCAACACCCCAGCCATG
β -Actin-F	CCTCGTAGATGGGCACAGT

Relative survival rate = $\begin{pmatrix} Mortality rate of the \\ control group - \\ Mortality rate of the \\ experimental group \end{pmatrix} / Mortality rate of the$ control group ×100%

Statistical analysis

Data are expressed as the mean \pm standard error of the mean (SEM). All statistical analysis were two-way ANOVA and post-test. Differences between two samples were evaluated using Student's *t*-test. Significant differences are indicated with an asterisk (*), where *p < 0.05, **p < 0.01, and ***p < 0.001 are considered to represent statistically significant differences in mean values. Statistical analyses were conducted using IBM SPSS Statistics 26.

Results

The $\Delta mcpC$ mutation results in a reduced stress defense capacity

Genomic DNA from the strains C50336, $\Delta mcpC$::*cat*, and $\Delta mcpC$ was used as templates for PCR identification with primers P3 and P4. The results (Figure 1A) showed bands at 1203 bp, 1,506 bp, and 489 bp, respectively, consistent with the expected sizes, indicating the successful knockout of the *mcpC* gene. Genomic DNA from the suspected complemented strain was used as a template, and primers P5 and P6 were employed for PCR identification. The results (Figure 1B) revealed a target band at approximately 1,572 bp, matching the expected size, confirming the successful construction of the *mcpC* complemented strain, designated as $\Delta mcpC + mcpC$.

To investigate whether the *mcpC* gene affects the resistance of *SE* to various environmental stresses, the survival rates of C50336 and $\Delta mcpC$ were compared under conditions of pH 3.5, pH 10, 42°C, and 10 mmol/L H₂O₂. The results showed that (Figure 1C), compared to C50336, the survival rate of $\Delta mcpC$ was significantly reduced under all tested conditions, indicating that the deletion of the *mcpC* gene weakens *SE*'s resistance to acid, alkaline, thermal, and oxidative stresses.

The *mcpC* gene does not affect biofilm formationand drug resistance

The biofilm formation ability of strains C50336, $\Delta mcpC$, and $\Delta mcpC + mcpC$ was evaluated. Tube assay results showed no significant differences in biofilm formation ability among the three strains (Figure 2A). Quantitative analysis using a 96-well plate assay also indicated no significant differences in biofilm formation among the strains (Figure 2B).

Detection of curli fimbriae, a major component of biofilms, revealed that all three strains formed red, rough colonies (Figure 2C), indicating their ability to produce curli fimbriae. Cellulose production analysis showed that colonies of all three strains exhibited the same fluorescence intensity under UV light (Figure 2D), confirming their ability to produce cellulose. These findings demonstrate that the *mcpC* gene does not affect the biofilm formation ability of *SE*.

The $\Delta mcpC$ mutation results in motility reduction

To assess whether the deletion of the *mcpC* gene affects the motility of *SE*, motility assays were conducted. The results showed that the average migration diameter of the $\Delta mcpC$ strain (17.5 mm) was significantly smaller than that of the wild-type C50336 strain (25 mm) and the complemented strain $\Delta mcpC + mcpC$ (21 mm) (Figure 3). These findings indicate that the deletion of the *mcpC* gene impairs the motility of *SE*.

Removal of *mcpC* weakens the invasion and intracellular survival of *SE*

The adhesion and invasion abilities of the $\Delta mcpC$ strain toward intestinal epithelial cells were assessed using human colorectal adenocarcinoma cells Caco-2. As shown in Figure 4A, the adhesion rate of $\Delta mcpC$ was comparable to that of the wild-type C50336 strain, but its invasion rate was significantly reduced.

The intracellular survival of $\Delta mcpC$ was evaluated using mousederived macrophages RAW264.7. The results revealed a significantly lower survival rate of $\Delta mcpC$ within macrophages compared to C50336 (Figure 4B). These findings indicate that the mcpC gene is critical for the invasion and intracellular survival capabilities of *SE*.

$\Delta mcpC$ exhibits increased LD₅₀ in mice

The virulence of C50336 and $\Delta mcpC$ strains was evaluated in mice via i.p. injection. Mice infected with $\Delta mcpC$ began to die on day 2, whereas those infected with C50336 showed mortality starting on day 3. In contrast, the control group exhibited no mortality and maintained normal behavior, including smooth fur, good mental state, and an absence of symptoms such as shivering, hunching, eye crusting, or disheveled fur.

The calculated LD₅₀ values (Table 5) were 6.3×10^5 CFU/mouse for C50336 and 1.9×10^7 CFU/mouse for $\Delta mcpC$, with the LD₅₀ of $\Delta mcpC$ being approximately 30 times higher than that of C50336 $(1.9 \times 10^7/6.3 \times 10^5 \approx 30)$. The LD₅₀ of the gene-complemented strain $\Delta mcpC + mcpC$ is 1.6×10^6 CFU/mouse. The results suggest that the deletion of the *mcpC* gene significantly attenuates the virulence of SE.

Removal of mcpC results in a down-regulation of the multiple virulence gene expressionof in *SE*

To investigate the mechanisms underlying the attenuated virulence of *SE* caused by the deletion of the *mcpC* gene, this study employed qPCR to examine the expression levels of various virulence genes. The results revealed that the deletion of *mcpC* significantly downregulated the expression of genes associated with bacterial motility (*fimD*), biofilm formation (*csgA*, *csgD*), cell membrane and cell wall integrity



(*hflK*, *lrp*), the type III secretion system (T3SS) (*sipA*, *sipB*, *pipB*), adhesion and invasion (*invH*), intracellular survival (*mgtC*, *sodC*), and nucleic acid exonuclease/endonuclease activity (*mrr1*) (Figure 5). These findings suggest that *mcpC* may regulate the expression of multiple virulence genes, thereby contributing to the overall virulence of SE.

Removal of *mcpC* results in reduced colonization and persistence of bacteria in the organ

Organ bacterial load is another critical indicator of *SE* virulence. In this study, the bacterial loads in the liver, spleen, and

cecum of mice infected with C50336 and $\Delta mcpC$ were assessed. After homogenization of the organs, bacterial counts were measured.

As shown in Figure 6, bacteria were isolated from the liver, spleen, and cecum on days 3, 7, and 14 post-infection. The colonization levels of both C50336 and $\Delta mcpC$ peaked on day 7 and subsequently declined. Notably, compared to C50336, $\Delta mcpC$ exhibited significantly lower bacterial loads in the liver, spleen, and cecum on day 3 and day 7; in the liver and cecum on day 14.

These findings indicate that while $\Delta mcpC$ can still colonize organs, its colonization ability in certain organs is significantly reduced, suggesting that the deletion of the mcpC gene diminishes the organ bacterial load and virulence of *SE*.



FIGURE 2

(A) Detection of biofilm formation in glass test tubes. (B) Qualitative detection of biofilm formation in microtiter plates, with absorbance measured at 570 nm. (C) Curli formation detection. (D) Cellulose formation detection.



$\Delta mcpC$ can induce mucosal, humoral, and cellular immune responses

To evaluate the ability of $\Delta mcpC$ to induce specific humoral and mucosal immune responses, serum IgG and fecal SIgA levels were measured in immunized mice using indirect ELISA. The results showed that at 14 dpi and 28 dpi, mice immunized with $\Delta mcpC$ exhibited significantly higher serum IgG levels compared to the control group (Figure 7A). Additionally, elevated SIgA levels were detected in fecal samples (Figure 7B). Both serum IgG and fecal SIgA levels increased significantly following the second immunization compared to the first. These findings suggest that $\Delta mcpC$ effectively induces robust specific humoral and mucosal immune responses, which are enhanced with repeated immunizations. Lymphocyte proliferation assays are a primary method for evaluating cellular immune responses. In this study, a lymphocyte proliferation assay was conducted using C50336 antigens as stimulants. The results revealed that lymphocyte proliferation, measured by the stimulation index (SI), was significantly higher in mice immunized with $\Delta mcpC$ compared to the control group (Figure 7C). Moreover, after the booster immunization, lymphocyte proliferation levels further increased. These findings indicate that $\Delta mcpC$ induces a strong specific immune response, which is enhanced with repeated immunizations.

The expression of different cytokines reflects the strength and polarization of the immune response. At 14 dpi and 28 dpi, the expression levels of *IL-1* β , *IL-2*, *IL-4*, *IL-6*, *IL-10*, *TNF-* α , and *IFN-* γ were analyzed using qPCR. The results showed that (Figures 7D,E), compared



TARIE 5	I D., of C50336	, $\triangle mcpC$ and $\triangle mcpC + mcpC$ in KM mice.
INDEL 9		

Strain	Inoculation dose (CFU/ mouse)	No. of deaths/ total No. of mice	LD ₅₀
C50336	2×10^7	5/5	6.3×10^{5}
	2×10^{6}	3/5	
	2×10^5	2/5	
	2×10^4	0/5	
	2×10^{3}	0/5	
$\Delta mcpC$	$3.8 imes 10^9$	5/5	$1.9 imes 10^7$
	$3.8 imes 10^8$	5/5	
	$3.8 imes 10^7$	3/5	
	$3.8 imes 10^6$	1/5	
	$3.8 imes 10^5$	0/5	
$\Delta mcpC + mcpC$	2×10^7	5/5	$1.6 imes 10^6$
	2×10^{6}	2/5	
	2×10^{5}	1/5	
	2×10^4	0/5	
	2×10^3	0/5	

to the control group, the expression levels of *IL-6*, *IL-10*, and *IFN-γ* significantly increased after the first immunization. Following the second immunization, *IL-6* and *IFN-γ* expression levels further increased, although *IL-6* remained similar to the levels observed after the first immunization, while *IFN-γ* continued to rise. These findings suggest that $\Delta mcpC$ effectively induces a strong immune response in mice.

$\Delta mcpC$ immunization provides powerful protective immune protection for mice

To further evaluate the protective immunity conferred by $\Delta mcpC$, this study challenged immunized mice with a virulent strain via i.p.

injection, recorded survival rates, and plotted survival curves. The results showed that mice in Group A (oral immunization with a dose of 2×10^7 CFU/mouse) exhibited 100% survival with no deaths recorded. In Group B (oral immunization with a dose of 2×10^6 CFU/mouse), partial mortality was observed. In contrast, all mice in Group C (non-immunized, challenged group) succumbed within 5 days, while mice in Group D (non-immunized, non-challenged control group) showed no mortality (Figure 8).

The percentage survival of mice at 14 days post-challenge is summarized in Table 6. The results showed that Groups A and D achieved a relative survival rate of 100%, Group B exhibited a survival rate of 60%, while Group C had no survivors. These findings indicate that oral immunization with $\Delta mcpC$ offers robust protection against *SE* infection in mice.

Discussion

SE can cause subclinical infections in adult livestock and poultry, leading to bacterial shedding through feces into the external environment. This creates challenges in pathogen eradication, resulting in severe systemic infections and high mortality rates in animals. The use of antibiotics and vaccination are key strategies for controlling Salmonella infections. However, widespread antibiotic use has led to the emergence of multidrug-resistant strains and severe drug residue issues, posing a significant threat to public health. Therefore, there is an urgent need for an effective vaccine to control this important zoonotic pathogen. As an intracellular pathogen, the host's cellular immune response plays a crucial role in limiting SE infections. Live attenuated vaccines are considered more effective than inactivated vaccines in combating both intestinal and systemic infections, as they can simultaneously stimulate robust cellular and humoral immune responses (Wang et al., 2022). In this study, a *mcpC* mutant strain of SE $\Delta mcpC$ exhibited significantly attenuated virulence and provided strong immune protection in mice.

During its pathogenesis, SE must overcome numerous adverse environmental conditions, including antimicrobial peptides,





temperature and pH fluctuations, and nutrient limitations (Rana et al., 2021). The ability to survive under these diverse environmental conditions is a fundamental characteristic of SE virulence (Arunima et al., 2020). In this study, the deletion of the mcpC gene impairs SE's ability to sense and respond to environmental changes, such as acid, alkali, heat, and oxidative stress. A large number of studies showed that Lon, CpxR, RfaL, and RpoS significantly affect the strain's stress defense capacity, thereby influencing the bacteria's pathogenicity (Kirthika et al., 2024; Badie et al., 2021). Thus, it is speculated that McpC helps *Salmonella* cope with challenges such as oxidative stress, high temperature, and hypoxia, and may influence the bacteria's virulence.

Numerous studies have demonstrated that *Salmonella* can form biofilms on a variety of contact surfaces (Römling et al., 2003). These biofilms exhibit high resistance to antimicrobial agents and contribute to the increased virulence of *Salmonella*, facilitating the establishment of chronic infections (Merino et al., 2019). Biofilm formation allows *Salmonella* to persist in poultry farming environments and contaminate poultry meat and eggs, which remain major vehicles for foodborne *Salmonella* outbreaks. Curli fimbriae and cellulose are the primary components of *Salmonella* biofilms. The $\Delta mcpC$ was no significant reduction in the formation of biofilm, curli fimbriae, and cellulose. But the expression levels of biofilm-related genes, *csgA* and *csgD*, were significantly reduced. One possible explanation is that



Production of *Salmonella*-specific antibodies in mouse sera and fecal. Levels of (A) IgG, (B) SIgA. (C) The lymphocyte proliferation was assessed at 14 dpi and 28 dpi using soluble antigen. At each time point, the mean stimulation index (SI) of the vaccinated group was significantly higher than that of the control group. (D,E) The expression level of cytokines *IL*-1 β , *IL*-2, *IL*-4, *IL*-6, *IL*-10, *TNF*- α and *IFN*- γ . The internal control gene were *gapdh* and β -actin, respectively.

while the deletion of the *mcpC* gene downregulates certain biofilmrelated genes, biofilm formation is regulated by the collective interaction of multiple genes. Bacterial motility is closely associated with chemotaxis. The combination of motility and chemotaxis enables bacteria to detect and pursue nutrients, allowing them to reach and maintain their preferred

colonization niches (Josenhans and Suerbaum, 2002). The level of motility plays a critical role in determining whether *Salmonella* can reach specific sites within the host, thereby influencing its virulence. We observed that the motility of the $\Delta mcpC$ was significantly reduced. The expression of the motility-associated gene *fimD was* down-regulated in $\Delta mcpC$. These findings suggest that the deletion of the *mcpC* gene impairs the motility of *SE*, which in turn affects its pathogenic process. This hypothesis is supported by many studies, such as the finding that the c-di-GMP binding effector STM0435 regulates flagella synthesis, controls biofilm formation, and affects Salmonella virulence (Dai et al., 2024). In addition, the knockout of YeiE reduces the expression of flagella-related genes such as fliA, flgM, and fliD in *Salmonella enterica*, leading to a decrease in flagella formation, which affects the bacteria's colonization of the intestines and its virulence (Westerman et al., 2021).

The pathogenic process of *Salmonella* involves adhesion and invasion of intestinal epithelial cells, survival and replication within host cells, and dissemination beyond the intestine. Invasion of host cells is a critical characteristic of *Salmonella* pathogenicity, while survival within macrophages is considered a more robust indicator of bacterial virulence (Fields et al., 1986; Eakley et al., 2011). We found that that the deletion of the *mcpC* gene impairs the invasion and intracellular survival capabilities of *SE*, both of which are closely linked to its virulence.

An ideal attenuated live vaccine strain should effectively withstand host-induced stress, provide robust protection against the target pathogen, and successfully colonize host lymphoid tissues, all while maintaining an avirulent profile (Pati et al., 2013). This study showed that the LD₅₀ of $\Delta mcpC$ was significantly increased, and the expression of multiple virulence genes is down-regulated, indicating a reduction



in its virulence. Following ingestion, *Salmonella* replicates in mucosaassociated lymphoid tissues, such as Peyer's patches, and disseminates via mesenteric lymph nodes to systemic organs, including the spleen and liver. The cecum is also a primary colonization site for *SE* in poultry. Organ bacterial load is a critical indicator of *Salmonella* virulence. Our results showed that $\Delta mcpC$ exhibited significantly reduced bacterial loads in these organs compared to the wild-type C50336 strain, indicating that mcpC deletion diminishes the pathogenicity of *SE*. Collectively, these findings suggest that the $\Delta mcpC$ mutant strain has significant potential as a candidate for an attenuated live vaccine.

Another critical requirement for developing an attenuated live vaccine is its ability to elicit both humoral and cellular immune responses in the host (Lin et al., 2017). A robust humoral immune response, particularly the secretion of secretory IgA (SIgA) in the intestinal mucosa, is essential for combating Salmonella infections (Roesler et al., 2006). Furthermore, as Salmonella is a facultative intracellular pathogen, cellular immune responses are crucial for effective host defense (Nandre et al., 2011). In this study, indirect ELISA revealed that $\Delta mcpC$ induced strong specific humoral and mucosal immune responses. Given that this pathogen primarily resides in the intestinal tract, IgA secreted into the intestinal lumen is likely to play a key role in protective immunity (Nandre et al., 2011). Our results also showed that $\Delta mcpC$ could induce a specific cellular immune response, and up-regulate the expression of IL-6, IL-10, and IFN-γ. IL-6 is pro-inflammatory cytokines that coordinate inflammatory and host defense responses (Huang and Sheng, 2010). IL-10, predominantly produced by Th2 cells, is a multifunctional antiinflammatory cytokine associated with immune regulation, defense, and infection (Yuan et al., 2022). IFN- γ , produced by activated T cells and natural killer (NK) cells, plays a vital role in host defense against intracellular pathogens such as Salmonella Typhimurium (Benbernou and Nauciel, 1994). Immune protection rate is a key indicator of vaccine efficacy, reflecting the vaccine's ability to protect against the target pathogen post-immunization. Oral immunization with $\Delta mcpC$ achieved a relative protection rate of 100%, demonstrating its strong protective efficacy in mice.

In summary, the *mcpC* gene is involved in multiple biological processes in *SE*, and its deletion significantly attenuates bacterial virulence in mice. The $\Delta mcpC$ strain was shown to induce robust immune responses and provide excellent immune protection in mice. These findings suggest that the $\Delta mcpC$ strain is a promising candidate for an attenuated live vaccine against *SE*, laying a preliminary foundation for the development of genetically engineered vaccines. Considering the broad host range of *SE*, future studies will validate its protective efficacy and safety in poultry and other animal models.

Group	Vaccination		Number	Challenge		Survivors/	Percent		
	Strain	Route	Dose (CFU)		Strain	Route	Dose (CFU)	total	survival (%)
A	$\Delta mcpC$	p.o.	2×10^7	10	C50336	i.p.	2×10^7	10/10	100
В	$\Delta mcpC$	p.o.	2×10^{6}	10	C50336	i.p.	2×10^7	6/10	60
С	PBS	p.o.	_	10	C50336	i.p.	2×10^7	0/10	0
D	PBS	p.o.	_	10	PBS	i.p.	_	10/10	100

TABLE 6 Protective effects of $\triangle mcpC$ in mice.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.

Ethics statement

The animal study was approved by Animal Care and Use Committee of Hebei Normal University of Science and Technology. The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions

LZ: Writing – original draft, Data curation, Formal analysis, Methodology, Supervision. LC: Data curation, Formal analysis, Methodology, Writing – original draft. XZ: Methodology, Writing – original draft. YaL: Methodology, Writing – original draft. QZ: Software, Writing – original draft. YuL: Software, Writing – original draft. NL: Software, Writing – original draft. QS: Supervision, Validation, Writing – review & editing. YZ: Funding acquisition, Writing – review & editing. TW: Conceptualization, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research

References

Arunima, A., Swain, S. K., Patra, S. D., Das, S., Mohakud, N. K., Misra, N., et al. (2020). Role of OB-fold protein YdeI in stress response and virulence of *Salmonella enterica* serovar Enteritidis. *J. Bacteriol.* 203:e00237. doi: 10.1128/JB.00237-20

Badie, F., Saffari, M., Moniri, R., Alani, B., Atoof, F., Khorshidi, A., et al. (2021). The combined effect of stressful factors (temperature and pH) on the expression of biofilm, stress, and virulence genes in *Salmonella enterica* ser. Enteritidis and Typhimurium. *Arch. Microbiol.* 203, 4475–4484. doi: 10.1007/s00203-021-02435-y

Benbernou, N., and Nauciel, C. (1994). Influence of mouse genotype and bacterial virulence in the generation of interferon-gamma-producing cells during the early phase of *Salmonella* Typhimurium infection. *Immunology* 83, 245–249

Berleman, J. E., and Bauer, C. E. (2005). Involvement of a Che-like signal transduction cascade in regulating cyst cell development in *Rhodospirillum centenum*. *Mol. Microbiol.* 56, 1457–1466. doi: 10.1111/j.1365-2958.2005.04646.x

Chousalkar, K., Gast, R., Martelli, F., and Pande, V. (2018). Review of egg-related salmonellosis and reduction strategies in United States, Australia, United Kingdom and New Zealand. *Crit. Rev. Microbiol.* 44, 290–303. doi: 10.1080/1040841X. 2017.1368998

Cote, C. K., Biryukov, S. S., Klimko, C. P., Shoe, J. L., Hunter, M., Rosario-Acevedo, R., et al. (2021). Protection elicited by attenuated live *Yersinia pestis* vaccine strains against lethal infection with virulent *Y. pestis. Vaccines* 9:161. doi: 10.3390/vaccines9020161

Dai, Y., Liu, R., Yue, Y., Song, N., Jia, H., Ma, Z., et al. (2024). A c-di-GMP binding effector STM0435 modulates flagellar motility and pathogenicity in *Salmonella*. *Virulence* 15:2331265. doi: 10.1080/21505594.2024.2331265

Datsenko, K. A., and Wanner, B. L. (2000). One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Natl. Acad. Sci. U.S.A.* 97, 6640–6645. doi: 10.1073/pnas.120163297

Deguchi, K., Yokoyama, E., Honda, T., and Mizuno, K. (2009). Efficacy of a novel trivalent inactivated vaccine against the shedding of *Salmonella* in a chicken challenge model. *Avian Dis.* 53, 281–286. doi: 10.1637/8516-110908-Reg.1

was funded by the Hebei Agriculture Research System (HBCT2024280205, HBCT2024280401, and HBCT2024280404); Central Government Guides Local Projects, Hebei Province, Department of Science and Technology (23626604G).

Acknowledgments

The authors thank Prof. Zheng Wang from Beijing University of Agriculture for their valuable help in our experiment.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The authors declare that no Gen AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Dong, H., Peng, D., Jiao, X., Zhang, X., Geng, S., and Liu, X. (2011). Roles of the spiA gene from *Salmonella enteritidis* in biofilm formation and virulence. *Microbiology* 157, 1798–1805. doi: 10.1099/mic.0.046185-0

Eakley, N. M., Bochsler, P. N., Gopal Reddy, P., and Fadl, A. A. (2011). Biological and virulence characteristics of the YqhC mutant of *Salmonella. Microbiol. Immunol.* 55, 830–840. doi: 10.1111/j.1348-0421.2011.00387.x

Fields, P. I., Swanson, R. V., Haidaris, C. G., and Heffron, F. (1986). Mutants of *Salmonella* Typhimurium that cannot survive within the macrophage are avirulent. *Proc. Natl. Acad. Sci. U.S.A.* 83, 5189–5193. doi: 10.1073/pnas.83.14.5189

Frye, J., Karlinsey, J. E., Felise, H. R., Marzolf, B., Dowidar, N., McClelland, M., et al. (2006). Identification of new flagellar genes of *Salmonella enterica* Serovar Typhimurium. *J. Bacteriol.* 188, 2233–2243. doi: 10.1128/JB.188.6.2233-2243.2006

Harkey, C. W., Everiss, K. D., and Peterson, K. M. (1994). The Vibrio cholerae toxincoregulated-pilus gene tcpI encodes a homolog of methyl-accepting chemotaxis proteins. *Infect. Immun.* 62, 2669–2678. doi: 10.1128/iai.62.7.2669-2678.1994

Hickman, J. W., Tifrea, D. F., and Harwood, C. S. (2005). A chemosensory system that regulates biofilm formation through modulation of cyclic diguanylate levels. *Proc. Natl. Acad. Sci. U.S.A.* 102, 14422–14427. doi: 10.1073/pnas.0507170102

Huang, Z.-B., and Sheng, G.-Q. (2010). Interleukin-1β with learning and memory. *Neurosci. Bull.* 26, 455–468. doi: 10.1007/s12264-010-6023-5

Huberman, Y. D., Velilla, A. V., and Terzolo, H. R. (2019). Evaluation of different live *Salmonella enteritidis* vaccine schedules administered during layer hen rearing to reduce excretion, organ colonization, and egg contamination. *Poult. Sci.* 98, 2422–2431. doi: 10.3382/ps/pez003

Ji, H. J., Jang, A.-Y., Song, J. Y., Ahn, K. B., Han, S. H., Bang, S. J., et al. (2022). Development of live attenuated *Salmonella* Typhimurium vaccine strain using radiation mutation enhancement technology (R-MET). *Front. Immunol.* 13:931052. doi: 10.3389/ fimmu.2022.931052 Josenhans, C., and Suerbaum, S. (2002). The role of motility as a virulence factor in bacteria. *Int. J. Med. Microbiol.* 291, 605–614. doi: 10.1078/1438-4221-00173

Kang, X., Yang, Y., Meng, C., Wang, X., Liu, B., Geng, S., et al. (2022). Safety and protective efficacy of *Salmonella pullorum* spiC and rfaH deletion rough mutant as a live attenuated DIVA vaccine candidate. *Poult. Sci.* 101:101655. doi: 10.1016/j.psj.2021.101655

Kirthika, P., Senevirathne, A., Park, S., Aganja, R. P., Kim, I.-S., Tae, H.-J., et al. (2024). Intracellular survival and pathogenicity modulation of *Salmonella* Lon, CpxR, and RfaL mutants used as live bacterial vectors under abiotic stress, unveiling the link between stress response and virulence in epithelial cells. *Int. J. Mol. Sci.* 25:9056. doi: 10.3390/ijms25169056

Li, Z., Lou, H., Ojcius, D. M., Sun, A., Sun, D., Zhao, J., et al. (2014). Methyl-accepting chemotaxis proteins 3 and 4 are responsible for *Campylobacter jejuni* chemotaxis and jejuna colonization in mice in response to sodium deoxycholate. *J. Med. Microbiol.* 63, 343–354. doi: 10.1099/imm.0.068023-0

Lin, Z., Tang, P., Jiao, Y., Kang, X., Li, Q., Xu, X., et al. (2017). Immunogenicity and protective efficacy of a *Salmonella enteritidis* sptP mutant as a live attenuated vaccine candidate. *BMC Vet. Res.* 13:194. doi: 10.1186/s12917-017-1115-3

Liu, X., Jiao, C., Ma, Y., Wang, Q., and Zhang, Y. (2018). A live attenuated Vibrio anguillarum vaccine induces efficient immunoprotection in Tiger puffer (*Takifugu rubripes*). Vaccine 36, 1460–1466. doi: 10.1016/j.vaccine.2018.01.067

Merino, L., Trejo, F. M., De Antoni, G., and Golowczyc, M. A. (2019). *Lactobacillus* strains inhibit biofilm formation of *Salmonella* sp. isolates from poultry. *Food Res. Int.* 123, 258–265. doi: 10.1016/j.foodres.2019.04.067

Milanez, G. P., Werle, C. H., Amorim, M. R., Ribeiro, R. A., Tibo, L. H. S., Roque-Barreira, M. C., et al. (2018). HU-lacking mutants of *Salmonella enterica* Enteritidis are highly attenuated and can induce protection in murine model of infection. *Front. Microbiol.* 9:1780. doi: 10.3389/fmicb.2018.01780

Nandre, R. M., Chaudhari, A. A., Matsuda, K., and Lee, J. H. (2011). Immunogenicity of a *Salmonella enteritidis* mutant as vaccine candidate and its protective efficacy against salmonellosis in chickens. *Vet. Immunol. Immunopathol.* 144, 299–311. doi: 10.1016/j. vetimm.2011.08.015

Negi, V. D., Singhamahapatra, S., and Chakravortty, D. (2007). Salmonella enterica serovar Typhimurium strain lacking pmrG-HM-D provides excellent protection against salmonellosis in murine typhoid model. *Vaccine* 25, 5315–5323. doi: 10.1016/j. vaccine.2007.05.015

Nishiyama, S., Takahashi, Y., Yamamoto, K., Suzuki, D., Itoh, Y., Sumita, K., et al. (2016). Identification of a *Vibrio cholerae* chemoreceptor that senses taurine and amino acids as attractants. *Sci. Rep.* 6:20866. doi: 10.1038/srep20866

Park, S., Jung, B., Kim, E., Hong, S.-T., Yoon, H., and Hahn, T.-W. (2020). Salmonella Typhimurium lacking YjeK as a candidate live attenuated vaccine against invasive Salmonella infection. Front. Immunol. 11:1277. doi: 10.3389/fimmu.2020.01277

Park, S., Jung, B., Kim, E., Yoon, H., and Hahn, T.-W. (2022). Evaluation of *Salmonella* Typhimurium lacking fruR, ssrAB, or hfq as a prophylactic vaccine against *Salmonella* lethal infection. *Vaccine* 10:1413. doi: 10.3390/vaccines10091413

Pasquevich, K. A., Ibañez, A. E., Coria, L. M., García Samartino, C., Estein, S. M., Zwerdling, A., et al. (2011). An oral vaccine based on U-Omp19 induces protection against *B. abortus* mucosal challenge by inducing an adaptive IL-17 immune response in mice. *PLoS One* 6:e16203. doi: 10.1371/journal.pone.0016203

Pati, N. B., Vishwakarma, V., Selvaraj, S. K., Dash, S., Saha, B., Singh, N., et al. (2013). *Salmonella* Typhimurium TTSS-2 deficient mig-14 mutant shows attenuation in immunocompromised mice and offers protection against wild-type *Salmonella* Typhimurium infection. *BMC Microbiol.* 13:236. doi: 10.1186/1471-2180-13-236

Rana, K., Nayak, S. R., Bihary, A., Sahoo, A. K., Mohanty, K. C., Palo, S. K., et al. (2021). Association of quorum sensing and biofilm formation with Salmonella virulence: story beyond gathering and cross-talk. *Arch. Microbiol.* 203, 5887–5897. doi: 10.1007/s00203-021-02594-y

Roesler, U., Heller, P., Waldmann, K.-H., Truyen, U., and Hensel, A. (2006). Immunization of sows in an integrated pig-breeding herd using a homologous inactivated *Salmonella* vaccine decreases the prevalence of *Salmonella* Typhimurium infection in the offspring. *J. Veterinary Med. B* 53, 224–228. doi: 10.1111/j.1439-0450.2006.00951.x

Römling, U., Bokranz, W., Rabsch, W., Zogaj, X., Nimtz, M., and Tschäpe, H. (2003). Occurrence and regulation of the multicellular morphotype in *Salmonella* serovars important in human disease. *Int. J. Med. Microbiol.* 293, 273–285. doi: 10.1078/1438-4221-00268

Sampedro, I., Parales, R. E., Krell, T., and Hill, J. E. (2014). *Pseudomonas* chemotaxis. *FEMS Microbiol Rev.* 39, 17–46. doi: 10.1111/1574-6976.12081

Upadhyaya, I., Upadhyay, A., Kollanoor-Johny, A., Darre, M., and Venkitanarayanan, K. (2013). Effect of plant derived antimicrobials on *Salmonella enteritidis* adhesion to and invasion of primary chicken oviduct epithelial cells *in vitro* and virulence gene expression. *Int. J. Mol. Sci.* 14, 10608–10625. doi: 10.3390/ijms140510608

Van Immerseel, F., Methner, U., Rychlik, I., Nagy, B., Velge, P., Martin, G., et al. (2005). Vaccination and early protection against non-host-specific *Salmonella* serotypes in poultry: exploitation of innate immunity and microbial activity. *Epidemiol. Infect.* 133, 959–978. doi: 10.1017/S0950268805004711

Wang, Y., Huang, C., Tang, J., Liu, G., Hu, M., Kang, X., et al. (2021). Salmonella pullorum spiC mutant is a desirable LASV candidate with proper virulence, high immune protection and easy-to-use oral administration. Vaccine 39, 1383–1391. doi: 10.1016/j.vaccine.2021.01.059

Wang, X., Kang, X., Pan, M., Wang, M., Zhang, J., and Song, H. (2022). Evaluation of the protective immune response induced by an rfbG-deficient *Salmonella enterica* serovar Enteritidis strain as a live attenuated DIVA (differentiation of infected and vaccinated animals) vaccine in chickens. *Microbiol. Spectr.* 10, e01574–e01522. doi: 10.1128/spectrum.01574-22

Westerman, T. L., McClelland, M., and Elfenbein, J. R. (2021). YeiE regulates motility and gut colonization in *Salmonella enterica* serotype Typhimurium. *mBio* 12:e0368020. doi: 10.1128/mBio.03680-20

Xiong, D., Song, L., Chen, Y., Jiao, X., and Pan, Z. (2023). Salmonella enteritidis activates inflammatory storm via SPI-1 and SPI-2 to promote intracellular proliferation and bacterial virulence. *Front. Cell. Infect. Microbiol.* 13:1158888. doi: 10.3389/fcimb.2023.1158888

Yang, W., Wang, L., Zhang, L., Qu, J., Wang, Q., and Zhang, Y. (2015). An invasive and low virulent *Edwardsiella tarda* esrB mutant promising as live attenuated vaccine in aquaculture. *Appl. Microbiol. Biotechnol.* 99, 1765–1777. doi: 10.1007/s00253-014-6214-5

Yin, J., Cheng, Z., Wu, Y., He, Q., Zhang, J., Yang, Z., et al. (2019). Characterization and protective efficacy of a *Salmonella* pathogenicity island 2 (SPI2) mutant of *Salmonella paratyphi* A. *Microb. Pathog.* 137:103795. doi: 10.1016/j.micpath.2019.103795

Yuan, Z., Song, H., Huang, Q., Liu, J., Sun, H., Meng, X., et al. (2022). Immune enhancement effects of inactivated vaccine against extracellular products of *Aeromonas caviae* AC-CY on crucian carp. *Fish Shellfish Immunol*. 127, 1001–1011. doi: 10.1016/j. fsi.2022.07.046

Zabalza-Baranguá, A., Poveda-Urkixo, I., Mena-Bueno, S., Ramírez, G. A., De Bolle, X., and Grilló, M. J. (2023). Vaccine properties of *Brucella melitensis* 16M Δ wzm and reactivation of placental infection in pregnant sheep. *Vaccine* 41, 1554–1566. doi: 10.1016/j.vaccine.2023.01.017

Zhang, Z., Du, W., Wang, M., Li, Y., Su, S., Wu, T., et al. (2020). Contribution of the colicin receptor CirA to biofilm formation, antibotic resistance, and pathogenicity of *Salmonella enteritidis. J. Basic Microbiol.* 60, 72–81. doi: 10.1002/jobm.201900418

Zhou, Y., Xiong, D., Guo, Y., Liu, Y., Kang, X., Song, H., et al. (2023). Salmonella enteritidis RfbD enhances bacterial colonization and virulence through inhibiting autophagy. *Microbiol. Res.* 270:127338. doi: 10.1016/j.micres.2023.127338